France· FR:67638864
NAMUSCLA 167 mg, gélules
A medicinal product containing chlorhydrate de mexilétine, registered in France by LUPIN EUROPE (ALLEMAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE DE MEXILÉTINE
- Manufacturer
- LUPIN EUROPE (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930172148plaquette(s) thermoformée(s) PVC PVDC aluminium de 100 gélule(s)EUR 2.48
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Chlorhydrate de mexilétine in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomMexiletine hydrochloride 200mg (Mexiletine 167mg) capsulesColonis Pharma Ltd
- CzechiaNAMUSCLALupin Europe GmbH, Frankfurt am Main
- FinlandNamusclaLupin Europe GmbH
- IrelandNamuscla 167 mg hard capsulesLupin Europe GmbH
- IcelandNamusclaLupin Europe GmbH
- NetherlandsNamuscla 167 mg harde capsulesLupin (Europe) Limited
- NorwayNamusclaLupin (Europe) Limited
- PolandNamusclaLupin Europe GmbH
Authorised across Europe · EMA
The same active substance is authorised in 7 EEA countries. Names it is sold under:
- Germany · Zunmyro, Zunmyro 200 Mg Hartkapseln
- Denmark · Dopital
- Finland · Dopital
- United Kingdom (Northern Ireland) · Mexiletine Hydrochloride Clinigen Healthcare, Mexiletine Hydrochloride Waymade
- Hungary · Ritalmex
- Norway · Dopital
- Sweden · Dopital
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0f3a71e0-6825-4a85-8b6a-e23a6c348d61 GET /v1/drugs/0f3a71e0-6825-4a85-8b6a-e23a6c348d61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "67638864",
"date_amm": "2018-12-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/18/1325",
"substance": "CHLORHYDRATE DE MEXILÉTINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about chlorhydrate de mexilétine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.